Ciphergen Biosystems, Inc. Equalizer Bead Technology Paper Recognized As ScienceDirect TOP25 Hottest Articles By Elsevier
FREMONT, Calif., June 2 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. announced today the receipt of a diploma from Elsevier publishers recognizing a recent paper as one of the top five papers downloaded from the website of the journal Clin Chim Acta. The paper titled, "Proteome Analysis in the Clinical Chemistry Laboratory; Myth or Reality?" provides an exhaustive overview of available technologies for proteomic analysis, particularly for the discovery of novel disease biomarkers. The paper describes the challenges of the dynamic range of the proteome, and demonstrates how Ciphergen's Equalizer Bead technology can help address this challenge. The paper was authored by Dr. Pier Giorgio Righetti at the University of Verona and Dr. Egisto Boschetti at Ciphergen, and their colleagues.
"The popularity of this paper demonstrates the urgent need for new technologies that can aid scientists and clinicians in the discovery of new protein markers. The novel technologies, such as Equalizer Beads, that we are developing will enable our collaborators and us to achieve this goal and develop novel high-value diagnostic tests," said Gail S. Page, President and CEO.
Copies of the manuscript can be downloaded at http://www.sciencedirect.com/science .
Ciphergen is dedicated to the discovery of protein biomarkers and panels of biomarkers and their development into protein molecular diagnostic tests that improve patient care; and to providing collaborative R&D services through its Biomarker Discovery Center(R) laboratories for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Ciphergen develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research and process proteomics applications. ProteinChip Systems enable protein discovery, validation, identification and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biological function at the protein level. Additional information about Ciphergen can be found at www.ciphergen.com.
Safe Harbor Statement
Note Regarding Forward-Looking Statements: For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding the usefulness of Ciphergen technologies in the discovery of protein biomarkers and the ability of Ciphergen to use such biomarkers in the creation of diagnostic tests. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the risk that Ciphergen may not be able to develop diagnostic tests based on the discoveries of biomarkers. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Form 10-K dated March 17, 2006, for further information regarding these and other risks of the Company's business.
NOTE: Ciphergen, ProteinChip and Biomarker Discovery Center are registered trademarks of Ciphergen Biosystems, Inc.Ciphergen Biosystems, Inc.
CONTACT: Sue Carruthers, Investor Relations of Ciphergen Biosystems, Inc.,+1-510-505 2297
Web site: http://www.ciphergen.com//